Woo Chi is Director of the Cell Line Development group at Samsung Biologics, managing multiple client and internal development projects while representing the CLD team in various settings. During his first 6 months at SBL, his CLD team executed projects with notably high pool and clone productivity, and simplified processes to lower the development cost. His team also developed a license-free CLD platform to reach 6 g/L titer, a transient expression system with competitive productivity and scalability, as well as in-house Master Cell Bank facilities. Woo has more than 20 years of experience in the pharmaceutical industry and academic research, and has held roles across CHO CLD, platform improvement, and assay development. Prior to joining Samsung Biologics, Woo served as a principal scientist at Evotec Biologics where he led CLD projects and established a new CDO lab with automation capabilities. Woo holds a doctorate degree in Genetics from the Yale School of Medicine.